Related Experiment Video
Updated: Aug 14, 2026
Forward Genetic Approaches in Chlamydia trachomatis
Published on: October 23, 2013
Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice
L Törmäkangas1, E Saario, D Bem David
1National Public Health Institute, P.O. Box 310, FIN-90101 Oulu, Finland. liisa.tormakangas@ktl.fi
Objectives:
The efficacy of telithromycin, a new ketolide antibiotic, was investigated in the treatment of acute Chlamydia pneumoniae infection in a mouse model.
Methods:
C57BL/6J mice were inoculated intranasally, and the effects of three different doses of telithromycin (25, 50 and 100 mg/kg) were assessed after 5 and 10 days of treatment. Lungs for culture, PCR, histopathology, and blood for serum samples were collected immediately after each treatment period and at 3 weeks post-inoculation. C. pneumoniae-specific antibodies were analysed, and the effect of treatment was assessed by culture, detection of C. pneumoniae DNA and determination of histopathological inflammatory changes in mouse lungs.
Results:
Culture negativity in the lungs was achieved with the higher doses, 50 and 100 mg/kg, after 10 days of treatment. C. pneumoniae DNA was not totally eradicated with the treatments, but the groups treated with 50 and 100 mg/kg doses for 10 days had the lowest DNA positivity rates (10%) 3 weeks after the inoculation. In lung histopathology, the efficacy of telithromycin on inflammatory changes was also dose-dependent: higher doses were more effective in reducing the inflammatory reaction. Overall, the 25 mg/kg dose had a weaker effect compared with the others.
Conclusions:
Telithromycin had both time- and dose-dependent effects on the eradication of chlamydia and on reducing infection-induced inflammatory changes in mouse lungs.
Insights
Telithromycin effectively treated Chlamydia pneumoniae lung infections in mice, with higher doses and longer treatment reducing bacteria and inflammation. This ketolide antibiotic shows promise for respiratory infections.
Area of Science:
- Microbiology
- Pharmacology
- Immunology
Background:
- Chlamydia pneumoniae is a significant cause of respiratory tract infections.
- Novel antibiotics are needed to combat bacterial infections effectively.
- Ketolide antibiotics offer a potential therapeutic option.
Purpose of the Study:
- To evaluate the efficacy of telithromycin in treating Chlamydia pneumoniae infection.
- To assess the impact of different telithromycin doses on bacterial load and lung inflammation.
- To investigate the time- and dose-dependent effects of telithromycin.
Main Methods:
- C57BL/6J mice were intranasally inoculated with Chlamydia pneumoniae.
- Three doses of telithromycin (25, 50, 100 mg/kg) were administered for 5 and 10 days.
- Lung cultures, PCR, histopathology, and serum antibody analysis were performed.
Main Results:
- Higher telithromycin doses (50 and 100 mg/kg) achieved lung culture negativity after 10 days.
- Bacterial DNA was not fully eradicated, but lower positivity rates were observed with higher doses.
- Telithromycin demonstrated a dose-dependent reduction in lung inflammatory changes.
Conclusions:
- Telithromycin exhibits time- and dose-dependent efficacy against Chlamydia pneumoniae infection.
- The antibiotic effectively reduces infection-induced inflammation in mouse lungs.
- Higher doses of telithromycin are more effective in bacterial eradication and reducing inflammation.
